Pharma boosts pipeline to 39 assets

Sandoz will add up to 10 biosimilars to its pipeline after signing an agreement with Shanghai Henlius Biotech worth up to US$322 million (A$453 million).

The initial agreement covers biosimilars of three blockbusters: Merck Healthcare’s Erbitux (cetuximab), Amgen’s Repatha (evolocumab), and GSK’s Benlysta (belimumab), which between them racked up more than US$6 billion in global sales last year.

It also includes an option for a biosimilar of Halozyme’s Hylenex recombinant human hyaluronidase, which increases the dispersion and absorption of injected medicines, to be used in the development of a biosimilar.

To see the whole article please log in.

Simon Webster

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here